VivoSeq
Other

Gastroenteritis

28

Pipeline Programs↗

2

Active Trials↗

14

Companies Involved↗

Gastroenteritis is an emerging landscape with 28 programs across 14 companies. The most active players are Roche, Merck & Co., Bristol-Myers Squibb. 8 therapies are approved with 13 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

78/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3R

RedHill Biopharma Limited

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3B

Bharat Biotech International Limited

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

79%

Small molecule

23 of 29 classified programs — the dominant modality here.

21%ALL OTHERSVaccine310%RNA therapy27%Monoclonal antibody13%

Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 97% of 33 pipeline programs.

Analysis

Trial Status

38

clinical trials

Completed25 · 66%
Terminated6 · 16%
Unknown status4 · 11%
Withdrawn1 · 3%
Active, not recruiting1 · 3%
Recruiting1 · 3%

Clinical Trials

Trial Activity

38 trials

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Recruiting·Moderna logoModerna·Phase 1/2·NCT05992935·1,405 enrolled
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
Active, not recruiting·Moderna logoModerna·Phase 3·NCT06592794·37,864 enrolled
Efficacy and Safety of Probiotics in the Treatment of Acute Gastroenteritis in Children
Completed·BBiocodex·Phase 4·NCT03539913·317 enrolled
Emergency Department Rapid Intravenous Rehydration (RIVR) for Pediatric Gastroenteritis
Completed·TThe Hospital for Sick Children·Phase 4·NCT00392145·226 enrolled
Ondansetron Versus Metoclopramide in Treatment of Vomiting in Gastroenteritis
Completed·HHamad Medical Corporation·Phase 4·NCT01165866·170 enrolled
Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis
Completed·WWashington University School of Medicine·Phase 2/3·NCT01773967·971 enrolled
Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis
Completed·GSK logoGSK·Phase 3·NCT00134732·150 enrolled
Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger
Completed·EEpicentre·Phase 3·NCT02145000·6,586 enrolled
Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis
Completed·GSK logoGSK·Phase 2·NCT00137930·250 enrolled
Efficacy of Gelatin Tannate in Treatment Acute Gastroenteritis in Children.
Completed·MMedical University of Warsaw·Phase 1·NCT02280759·72 enrolled
Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis
Completed·UUniversity of Calgary·Phase 3·NCT03851835·1,030 enrolled
Symptomatic Treatment of Acute Gastroenteritis
Completed·IIRCCS Burlo Garofolo·Phase 3·NCT01257672·356 enrolled
Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis in a Pediatric Emergency Department
Completed·TThe Hospital for Sick Children·N/A·NCT00120744
Pedialyte or Gatorade for Viral Gastroenteritis in Adults: a Randomized, Controlled Trial
Completed·—·N/A·NCT00257374
Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France.
Completed·UUniversity Hospital, Brest·Phase 4·NCT00740935·7,204 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)